FDA Accepts for Priority Review BLA for Epcoritamab in Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D., Executive Vice President & Chief Medical Officer, Head of Experimental Medicines at Genmab, an international biotechnology company, discusses the announcement from Genmab and Abbvie that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application for epcoritamab (DuoBody ®-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. The target action date for the FDA decision is May 21, 2023. For more information visit clinicaltrials.gov www.genmab.com
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Therapy. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Therapy and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Therapy?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Tahamtan (Tahi) Ahmadi, M.D., Ph.D., Executive Vice President & Chief Medical Officer, Head of Experimental Medicines at Genmab
Dr. Ahmadi joined Genmab in 2017 and became the Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. He holds an M.D. from the University of Cologne (Germany) and a Ph.D. from the University of Freiburg (Germany) and has expertise in translational research, strategic product development, global regulatory submissions and clinical development. Prior to joining Genmab, Dr. Ahmadi was head of experimental medicine and early development oncology at Janssen and a member of the Senior Leadership Team for Oncology.
During his time at Janssen, he led the global development of daratumumab including clinical R&D and medical affairs strategy across indications and was instrumental in the clinical development and initial FDA NDA submission for Ibrutinib. Prior to joining Janssen, Dr. Ahmadi was a faculty member of the Department of Hematology and Oncology at the University of Pennsylvania. Dr. Ahmadi is an author on a number of scientific articles that have been published in journals such as NEJM, Lancet, JCO and Blood, among others.
Dr. Ahmadi is a registered manager of Genmab with the Danish Business Authority.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
